Title : MicroRNA-155 in mononuclears as a predictor of acute kidney injury in patients with ST-elevation myocardial infarction
Abstract:
Acute kidney injury (AKI) in patients with ST-elevation myocardial infarction (STEMI) is a substantial problem, particularly, its prediction and therapy approaches. Earlier we analyzed the change of microRNAs subset in different blood fractions (plasma, platelets, mononuclears), and microRNA-155 have demonstrated the profound difference in STEMI patients compared to control persons. In this study, we have estimated the level of microRNA-155 in blood plasma and mononuclears in patients with STEMI using RT real-time PCR, and built the model for AKI prediction. Level of microRNA-155 in mononuclears on day 1 is a positive predictor of day 7 eGFR (regression coefficient 21.75, p = 0.008), while level of microRNA-155 in plasma is weaker but negative predictor (model p = 0.002, R squared: 0.36).
|
|
Estimate |
Std. Error |
t value |
Pr(>|t|) |
|
(Intercept) |
71.86 |
4.085 |
17.591 |
2.57e-16 *** |
|
microRNA-155 in plasma |
-0.63 |
0.261 |
-2.420 |
0.023 * |
|
microRNA-155 in mononuclears |
21.75 |
7.617 |
2.856 |
0.008 ** |
Among three of studied fractions, the most prominent and reproducible results are shown for microRNA-155 in mononuclears: its level on day 7 is 12 times higher compared to day 1 (paired Wilcoxon test, p = 3.57e-05). At day 7, microRNA-155 in mononuclears was positively correlated with eGFR (Spearman’s rho = 0.69) and plasma level of microRNA-155 was negatively correlated with eGFR (Spearman’s rho = -0.77). Furthermore, we observe less frequency of AKI in patients who have 5-fold or more increase of microRNA-155 in mononuclears than in other those who have not (p = 0.045). In conclusion, microRNA-155 in mononuclears can be considered as a positive predictive factor regarding renal function in patients with STEMI, and its 5-fold or more increase in 7 days after STEMI onset can be considered as protective against AKI.
Audience Take Away:
- The abstract highlights that AKI is a significant problem in patients with STEMI. This information provides an understanding of the context and the importance of studying AKI in this specific patient population.
- Differences in microRNA-155 Expression: analysis of microRNAs, specifically microRNA-155, in different blood fractions (plasma, platelets, mononuclears). It states that microRNA-155 demonstrated a profound difference in STEMI patients compared to control individuals. This finding suggests that microRNA-155 may play a role in the development or progression of AKI in STEMI patients.
- Research Expansion: Faculty members can use this research as a foundation to expand their own investigations related to microRNAs, AKI, and STEMI. They can build upon the findings presented in this study and conduct further experiments or studies to explore related aspects or specific mechanisms underlying the role of microRNA-155 in AKI prediction and therapy.
- Collaborative Research: The findings can also serve as a basis for collaboration among faculty members working in related fields. They can discuss and explore possibilities for joint research projects, combining their expertise to further investigate the role of microRNA-155 and its implications for AKI in STEMI.
- Clinical Applications: Faculty members involved in clinical practice can utilize the research findings to improve patient care and develop new strategies for AKI prevention or treatment. They can incorporate the knowledge gained from this study into their clinical decision-making processes and treatment plans.
- In conclusion, the audience will gain knowledge about the association between microRNA-155 and AKI in patients with STEMI. They will learn about the predictive potential of microRNA-155 levels, correlations with renal function, and the possible protective effect of its increase.
